Pfizer’s Rheumatoid Arthritis Medication Increases
Risk of Cancer and Blood Clots Compared to Alternatives
Recent Study Confirms Risk of Cancer, DVT Elevated with Use of Xeljanz® Compared to Other Available Medications
Pfizer, the maker of drug Xeljanz®, announced the results of a study compelled by the Food and Drug Administration following reports of possible elevated levels of cancer and cardiovascular incidents, including deep vein thrombosis and pulmonary embolism compared to other available autoimmune medications. The study was designed to evaluate the safety of Xeljanz® versus other similar medications, called TNF inhibitors in patients with rheumatoid arthritis.
The post-marketing study was compelled after studies showed increased risk of cancers and was intended to show a “non-inferiority” safety profile of Xeljanz® compared to competitors. However, the study showed the opposite, confirming Xeljanz® carries an increased risk of certain cancers and cardiovascular events compared with other medications.
The study demonstrates that Xeljanz® is a more dangerous medication compared to readily available alternatives due to an increased risk in the development of these diseases.
Xeljanz® has been approved for treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis and Polyarticular Course Juvenile Idiopathic Arthritis.
If you or a loved one suffered from a blood clot or developed any of [type of cancer] after taking any dose ofXeljanz® or Xeljanz XR® for ulcerative colitis, rheumatoid arthritis, or psoriatic arthritis, please reach out today for a free consultation by filling out our intake form on this page or calling 202-780-5153, ext. 101. Likewise, if you have been prescribed Xeljanz® in the past and are concerned about an increased risk of the development of cancer, please reach out as well.
Someone will be in touch with you soon and, we can help you explore your legal options. You may be able to seek compensation for your injuries, including medical expenses, lost wages, and pain and suffering.